Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516161 · ClinicalTrials.gov registry record
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,180
- Enrollment target
NCT04516161: Completed study, sponsored by Bayer.
NCT04516161 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04516161 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,180 participants
- Enrollment target
Study Summary
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,180 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2021-03-31 |
What the finished NCT04516161 record still lists
NCT04516161 is an observational study that tracks outcomes without assigning an intervention. Its 1,180 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Radium-223 dichloride (Xofigo, BAY88-8223) is the first listed.
NCT04516161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04516161 about?
NCT04516161 is a clinical study titled "EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)". In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosteron...
What is the current status of trial NCT04516161?
This trial is currently completed. The enrollment target is 1,180 participants. The study started on 2020-08-03. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT04516161?
The interventions under investigation include: Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT04516161?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI